Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05176223

68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer

Conditions: Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE2
Enrollment: 26
Sponsor: Mayo Clinic

Location: Mayo Clinic in Rochester Rochester Minnesota

Summary

This phase II trial tests whether 68-Gallium prostate specific membrane antigen (68Ga-PSMA) positron emission tomography (PET) imaging can improve the diagnosis and management of liver cancer that has spread to other parts of the body (advanced). PSMA is a protein that appears in large amounts on the surface of liver cancer cells. The radioactive chemical compound (68Ga-PSMA) has been designed to circulate through the body and attach itself to the PSMA protein on liver cancer cells. A PET scan is then used to detect the location of the tumor cells. 68Ga-PSMA PET may improve upon the diagnosis and management of liver cancer.

Eligibility Criteria

Inclusion Criteria: * Patient with pathologically confirmed HCC not amenable to curative resection, transplantation or ablative therapies * Have radiographically measurable disease by RECIST * Eligible for atezolizumab/bevacizumab front line therapy * Male or female with age greater than 18 years, with the capacity and willingness to provide written informed consent Exclusion Criteria: * Pregnant and/or breast-feeding patients. A negative pregnancy test within 48 hours of the PET scan * Patients with higher than the weight/size limitations of PET/CT scanner

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05176223). StuddyBuddy aggregates publicly available trial information.